Greenwich equity firm Sagard Capital Partners completed its $169.5 million buyout of New York fertility-and vein-care clinic operator IntegraMed America Inc., authorities say.
Sagard's cash layout of $14.04 a share means IntegraMed, of Purchase, N.Y., is no longer a public company, whose shares have been delisted from Nasdaq, officials said.
Sagard was among IntegraMed's leading investors.
The parties announced their deal in June.
IntegraMed's outpatient facilities operate under the names Attain Fertility Centers and Vein Clinics of America.
Sagard Managing Partner Dan Friedberg said the model is to expand IntegraMed's patient base nationwide as well as develop complementary business opportunities.
Jefferies & Co. was financial advisor and New York City law firm Dorsey & Whitney LLP was legal advisor to IntegraMed.
Stamford law firm Finn Dixon & Herling LLP was Sagard's legal counsel.